WO2012163501A1 - Nasale pharmazeutische formulierung enthaltend fluticason - Google Patents
Nasale pharmazeutische formulierung enthaltend fluticason Download PDFInfo
- Publication number
- WO2012163501A1 WO2012163501A1 PCT/EP2012/002222 EP2012002222W WO2012163501A1 WO 2012163501 A1 WO2012163501 A1 WO 2012163501A1 EP 2012002222 W EP2012002222 W EP 2012002222W WO 2012163501 A1 WO2012163501 A1 WO 2012163501A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation according
- nasal
- fluticasone
- formulation
- treatment
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 3
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 238000009472 formulation Methods 0.000 claims abstract description 28
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 206010039094 Rhinitis perennial Diseases 0.000 claims abstract description 5
- 238000011321 prophylaxis Methods 0.000 claims abstract description 5
- 206010010741 Conjunctivitis Diseases 0.000 claims abstract description 4
- 229960002714 fluticasone Drugs 0.000 claims description 14
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 14
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 229960000289 fluticasone propionate Drugs 0.000 claims description 12
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims description 8
- 239000007921 spray Substances 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 5
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 5
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 4
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 4
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940067107 phenylethyl alcohol Drugs 0.000 claims description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229940068968 polysorbate 80 Drugs 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 3
- 239000002738 chelating agent Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- 239000000375 suspending agent Substances 0.000 claims description 2
- 239000002357 osmotic agent Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 abstract description 10
- 239000004480 active ingredient Substances 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 5
- 208000022719 perennial allergic rhinitis Diseases 0.000 abstract description 4
- 230000001932 seasonal effect Effects 0.000 abstract description 4
- 208000037916 non-allergic rhinitis Diseases 0.000 abstract description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 8
- 208000026935 allergic disease Diseases 0.000 description 8
- 230000007815 allergy Effects 0.000 description 8
- 201000010105 allergic rhinitis Diseases 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 206010039085 Rhinitis allergic Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000007922 nasal spray Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 229940097496 nasal spray Drugs 0.000 description 3
- -1 polyoxyethylene Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 208000000592 Nasal Polyps Diseases 0.000 description 2
- 206010028735 Nasal congestion Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 208000036284 Rhinitis seasonal Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 208000017022 seasonal allergic rhinitis Diseases 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 206010001076 Acute sinusitis Diseases 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010052437 Nasal discomfort Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 125000005501 benzalkonium group Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940033835 flonase Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000005496 tempering Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- 238000004481 total suppression of sideband Methods 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Definitions
- the present invention relates to a nasal formulation containing as active ingredient an intranasal corticosteroid.
- the invention relates to a nasal formulation comprising fluticasone or its pharmaceutically usable esters or salts.
- the invention relates to a nasal formulation containing fluticasone propionate.
- the present invention further relates to a method for prophylaxis or
- nasal Formulation containing as active ingredient an intranasal corticosteroid, preferably fluticasone or its pharmaceutically usable ester or salts.
- the invention relates to a method for the prophylaxis or treatment of seasonal or perennial allergic rhinitis and rhinoconjunctivitis with a nasal formulation containing fluticasone propionate.
- the present invention furthermore relates to a process for the preparation of a nasal formulation containing as active ingredient an intranasal corticosteroid, preferably fluticasone or its pharmaceutically usable esters or salts.
- the invention relates to a method for
- Allergic rhinitis is a global health problem with increasing prevalence. At present, about 500 million people worldwide are affected. Symptoms of allergic rhinitis affect social life, sleep, and learning
- intranasal corticosteroids are the treatment of choice (LaForce J Allergy Clin Immunol 1999; 103: S388-S94; Brozek et al., J Allergy Clin Immunol 2010; 126: 466-76, Wallace J Allergy Clin Immunol. 2008 Aug; 122 (2 Suppl): S1-84).
- Fluticasone is an active ingredient in the class of corticosteroids and is becoming
- Formulations for nasal application in the market are, for example, Flutide, Flonase or Fluticasone Propionate Nasal Spray 50 pg (Roxane Laboratories).
- the active ingredient fluticasone is microfine dispersed in the liquid.
- the object of the present invention is to provide a corticosteroid-containing drug for the treatment of allergic rhinitis with improved efficacy.
- the object is achieved by a nasal formulation of fluticasone, in particular fluticasone propionate, containing as excipients microcrystalline cellulose +
- Na carboxymethylcellulose (Avicel CL 61 1), disodium edetate, polysorbate 80, glycerol, benzalkonium chloride, phenylethyl alcohol.
- the nominal dose of fluticasone propionate is 50 pg.
- a key parameter for the efficiency of locally applied and locally acting substances is the nominal dose of the drug being administered. In general, it is assumed that medicinal products with the same nominal dose of the same active substance show comparable effects. (Le Souef, Allergy 1999, 54, S93-96)
- the formulation according to the invention has the advantage that the corticoid futicasone is better available locally in the nose despite the same nominal dose (Derendorf, et al., 2012 Br J Clin Pharmacol accepted) and can exert a stronger effect there:
- Table 1 shows the comparison between the formulation according to the invention according to Example 1 and a formulation of the prior art (Fluticasone Propionate Nasal Spray 50 mg (Roxane Laboratories)) with the same nominal dose. The results are given as the baseline difference, if not otherwise
- iTNSS Instantaneous Total Nasal Symptom Score
- TOSS Total Ocular Symptom Score
- Fluticasone values in [pg / ml] are plotted over time in Figure 1 and show the extent of improvement in availability:
- inventions comprise, instead of fluticasone or one of its pharmaceutically usable esters or salts, one or more active substances from the group of intranasal corticosteroids, budesonides,
- Beclomethasone mometasone, triamcinolone, dexamethasone, ciclesonide or their pharmaceutically acceptable salts or esters.
- the formulation optionally contains one or more excipients from the group of suspending agents / thickeners, such as carboxymethylcellulose, hydroxymethylcellulose, methylcellulose, gelatin, polyvinylpyrrolidone,
- Na carboxymethylcellulose (Avicel CL 61 1), chelating agents, preferably disodium edetate, wetting agents, such as polyoxyethylene derivatives of fatty acids or
- Polyoxyethylene derivatives of fatty acid partial esters of sorbitol anhydrides preferably polysorbate 80, osmotically active substances, such as sucrose, glucose, sorbitol, Propylene glycol, NaCl preferably glycerol and preservatives, such as thiomersal, benzyl alcohol, alkonium and benzalkonium salts, Chlorhexidinglukonat, preferably benzalkonium chloride and phenylethyl alcohol.
- the preparation of the formulation according to the invention is carried out, for example, by tempering purified water to 30-40.degree. Become one after another
- Disodium edetate and glycerol added and each about 5 min. mixed.
- Microcrystalline cellulose and Na carboxymethyl cellulose are passed through
- Phenylethyl alcohol is added and mixed with stirring for about 10 minutes. After addition of purified water, the suspension for about 30 min.
- the formulation is administered via spray bottles with commercially available pumps, such as those from the companies Aptar or MeadWestvaco
- the formulation according to the invention is applied with a droplet size of not more than 150 ⁇ m, preferably between 50 ⁇ m and 100 ⁇ m, more preferably between 75 ⁇ m and 95 ⁇ m, in half of the droplets in the administered dosage unit.
- a dosage unit contains between 10 and 200 g, preferably between 25 and 100 g, more preferably between 40 and 60 pg of the intranasal corticosteroid.
- one unit dose contains 50 pg fluticasone propionate.
- the dosage unit of the intranasal corticosteroid is administered in a volume between 50 and 250 ⁇ , preferably between 100 and 150 ⁇ .
- one unit dose of fluticasone propionate is administered in a volume of 137 ⁇ per puff.
- 1-2 sprays are administered once or twice a day for a total of 2-8 sprays a day, more preferably one for each nostril, 1 spray in the morning and 1 spray in the evening for a total of 4 sprays per day.
- compositions are given by way of example, without the invention being restricted thereby:
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2012265231A AU2012265231B2 (en) | 2011-05-27 | 2012-05-24 | Nasal pharmaceutical formulation |
CN201280024623.1A CN103561721A (zh) | 2011-05-27 | 2012-05-24 | 包含氟替卡松的鼻用药物配制剂 |
JP2014511774A JP2014515360A (ja) | 2011-05-27 | 2012-05-24 | フルチカゾンを含む鼻用医薬製剤 |
MX2013013879A MX2013013879A (es) | 2011-05-27 | 2012-05-24 | Formulacionn farmaceutica nasal que comprende fluticasona. |
EA201391686A EA025203B1 (ru) | 2011-05-27 | 2012-05-24 | Фармацевтический состав для назального применения, содержащий флутиказон |
US14/122,561 US20140194400A1 (en) | 2011-05-27 | 2012-05-24 | Nasal Pharmaceutical Formulation |
CA2836025A CA2836025A1 (en) | 2011-05-27 | 2012-05-24 | Nasal pharmaceutical formulation comprising fluticasone |
EP12745769.5A EP2714005A1 (de) | 2011-05-27 | 2012-05-24 | Nasale pharmazeutische formulierung enthaltend fluticason |
NZ616149A NZ616149B2 (en) | 2011-05-27 | 2012-05-24 | Nasal Pharmaceutical Formulation Comprising Fluticasone |
BR112013030260A BR112013030260A2 (pt) | 2011-05-27 | 2012-05-24 | formulação farmacêutica nasal contendo fluticasona |
IL229497A IL229497A0 (en) | 2011-05-27 | 2013-11-19 | An epic pharmaceutical formulation containing fluticasone |
ZA2013/08905A ZA201308905B (en) | 2011-05-27 | 2013-11-25 | Nasal pharmaceutical formulation comprising fluticasone |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102011103347.9A DE102011103347B4 (de) | 2011-05-27 | 2011-05-27 | Nasale pharmazeutische Formulierung |
DE102011103347.9 | 2011-05-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012163501A1 true WO2012163501A1 (de) | 2012-12-06 |
WO2012163501A9 WO2012163501A9 (de) | 2013-03-07 |
Family
ID=46642459
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2012/002222 WO2012163501A1 (de) | 2011-05-27 | 2012-05-24 | Nasale pharmazeutische formulierung enthaltend fluticason |
Country Status (14)
Country | Link |
---|---|
US (1) | US20140194400A1 (de) |
EP (1) | EP2714005A1 (de) |
JP (1) | JP2014515360A (de) |
CN (1) | CN103561721A (de) |
AU (1) | AU2012265231B2 (de) |
BR (1) | BR112013030260A2 (de) |
CA (1) | CA2836025A1 (de) |
DE (1) | DE102011103347B4 (de) |
EA (1) | EA025203B1 (de) |
GE (1) | GEP201606577B (de) |
IL (1) | IL229497A0 (de) |
MX (1) | MX2013013879A (de) |
WO (1) | WO2012163501A1 (de) |
ZA (1) | ZA201308905B (de) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105263551A (zh) * | 2013-03-26 | 2016-01-20 | 奥普蒂诺斯公司 | 鼻腔给药 |
CN106470724A (zh) * | 2014-06-25 | 2017-03-01 | 奥普蒂诺斯公司 | 鼻腔给药 |
US11554229B2 (en) | 2013-03-26 | 2023-01-17 | OptiNose Inc. | Nasal administration |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103893120A (zh) * | 2012-12-27 | 2014-07-02 | 重庆华邦制药有限公司 | 提高了稳定性的丙酸氟替卡松喷雾剂 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020165211A1 (en) * | 2000-08-05 | 2002-11-07 | Keith Biggadike | Formulation containing anti-inflammatory androstane derivative |
US20040208830A1 (en) * | 2003-04-16 | 2004-10-21 | Imtiaz Chaudry | Nasal pharmaceutical formulations and methods of using the same |
WO2010141834A1 (en) * | 2009-06-05 | 2010-12-09 | Aciex Therapeutics, Inc. | Ophthalmic formulations of fluticasone and methods of use |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA008829B1 (ru) * | 2002-12-17 | 2007-08-31 | Нэстек Фармасьютикал Кампани Инк. | Композиции и способы для усовершенствованной доставки пептидов, связывающихся с y-рецепторами, которую осуществляют через слизистые оболочки, и способы лечения и предотвращения ожирения |
US20070178051A1 (en) * | 2006-01-27 | 2007-08-02 | Elan Pharma International, Ltd. | Sterilized nanoparticulate glucocorticosteroid formulations |
MX2008010350A (es) * | 2006-02-09 | 2008-10-31 | Schering Corp | Formulaciones farmaceuticas. |
WO2007146869A1 (en) * | 2006-06-09 | 2007-12-21 | Parion Sciences, Inc. | Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity |
JP2010195716A (ja) * | 2009-02-25 | 2010-09-09 | Takeda Chem Ind Ltd | 点鼻睡眠導入剤 |
JP2013512259A (ja) * | 2009-11-30 | 2013-04-11 | ウイスコンシン アラムニ リサーチ ファンデーション | 2−メチレン−19,26−ノル−(20S)−1α−ヒドロキシビタミンD3 |
-
2011
- 2011-05-27 DE DE102011103347.9A patent/DE102011103347B4/de not_active Expired - Fee Related
-
2012
- 2012-05-24 AU AU2012265231A patent/AU2012265231B2/en not_active Ceased
- 2012-05-24 EP EP12745769.5A patent/EP2714005A1/de not_active Withdrawn
- 2012-05-24 US US14/122,561 patent/US20140194400A1/en not_active Abandoned
- 2012-05-24 MX MX2013013879A patent/MX2013013879A/es not_active Application Discontinuation
- 2012-05-24 EA EA201391686A patent/EA025203B1/ru not_active IP Right Cessation
- 2012-05-24 GE GEAP201213337A patent/GEP201606577B/en unknown
- 2012-05-24 CN CN201280024623.1A patent/CN103561721A/zh active Pending
- 2012-05-24 BR BR112013030260A patent/BR112013030260A2/pt not_active IP Right Cessation
- 2012-05-24 CA CA2836025A patent/CA2836025A1/en not_active Abandoned
- 2012-05-24 JP JP2014511774A patent/JP2014515360A/ja active Pending
- 2012-05-24 WO PCT/EP2012/002222 patent/WO2012163501A1/de active Application Filing
-
2013
- 2013-11-19 IL IL229497A patent/IL229497A0/en unknown
- 2013-11-25 ZA ZA2013/08905A patent/ZA201308905B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020165211A1 (en) * | 2000-08-05 | 2002-11-07 | Keith Biggadike | Formulation containing anti-inflammatory androstane derivative |
US20040208830A1 (en) * | 2003-04-16 | 2004-10-21 | Imtiaz Chaudry | Nasal pharmaceutical formulations and methods of using the same |
WO2010141834A1 (en) * | 2009-06-05 | 2010-12-09 | Aciex Therapeutics, Inc. | Ophthalmic formulations of fluticasone and methods of use |
Non-Patent Citations (11)
Title |
---|
BOUSQUET ET AL., ALLERGY, vol. 63, no. 86, April 2008 (2008-04-01), pages 8 - 160 |
BOUSQUET, J ALLERGY CLIN IMMUNOL., vol. 124, no. 3, September 2009 (2009-09-01), pages 428 - 33 |
BROZEK ET AL., J ALLERGY CLIN IMMUNOL, vol. 126, 2010, pages 466 - 76 |
CARR ET AL., J ALLERGY CLIN IMMUNOL, vol. 129, no. 5, 2012, pages 1282 - 1289 |
DERENDORF ET AL., BR J CLIN PHARMACOL, 2012 |
DERENDORF HARTMUT ET AL: "Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, vol. 74, no. 1, July 2012 (2012-07-01), pages 125 - 133, XP002685929 * |
HAMPEL ET AL., ANN ALLERGY ASTHMA IMMUNOL., vol. 105, 2010, pages 168 - 73 |
HARTMUT DERENDORF: "Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray - Online Supplement", BR J CLIN PHARMACOL., 22 February 2012 (2012-02-22), pages S1 - S12, XP055042267, Retrieved from the Internet <URL:http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2012.04222.x/abstract> [retrieved on 20121025] * |
LAFORCE, J ALLERGY CLIN IMMUNOL, vol. 103, 1999, pages S388 - S94 |
LE SOUEF, ALLERGY, vol. 54, 1999, pages 93 - 96 |
WALLACE, J ALLERGY CLIN IMMUNOL., vol. 122, no. 2, August 2008 (2008-08-01), pages 1 - 84 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105263551A (zh) * | 2013-03-26 | 2016-01-20 | 奥普蒂诺斯公司 | 鼻腔给药 |
US11554229B2 (en) | 2013-03-26 | 2023-01-17 | OptiNose Inc. | Nasal administration |
CN106470724A (zh) * | 2014-06-25 | 2017-03-01 | 奥普蒂诺斯公司 | 鼻腔给药 |
Also Published As
Publication number | Publication date |
---|---|
ZA201308905B (en) | 2015-03-25 |
EA025203B1 (ru) | 2016-11-30 |
WO2012163501A9 (de) | 2013-03-07 |
DE102011103347A1 (de) | 2012-11-29 |
GEP201606577B (en) | 2016-11-25 |
IL229497A0 (en) | 2014-01-30 |
AU2012265231B2 (en) | 2016-09-08 |
EP2714005A1 (de) | 2014-04-09 |
NZ616149A (en) | 2015-11-27 |
DE102011103347B4 (de) | 2014-10-30 |
US20140194400A1 (en) | 2014-07-10 |
CN103561721A (zh) | 2014-02-05 |
JP2014515360A (ja) | 2014-06-30 |
MX2013013879A (es) | 2014-01-23 |
EA201391686A1 (ru) | 2014-03-31 |
BR112013030260A2 (pt) | 2016-12-06 |
CA2836025A1 (en) | 2012-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69738000T2 (de) | Neue Arzneiformulierung enthaltend Budesonide | |
DE69938390T2 (de) | Verwendung einer zusammensetzung welche formoterol und budesonide enthält, zur verhinderung oder behandlung eines akuten astmazustandes | |
EP1216046B1 (de) | Neue kombination von loteprednol und antihistaminika | |
EP1265615B1 (de) | Neue kombination nichtsedierender antihistaminika mit substanzen, die die leukotrienwirkung beeinflussen, zur behandlung der rhinitis/konjunktivitis | |
DE69834955T2 (de) | Neue Verwendung von Budesonide und Formoterol | |
EP2214658B1 (de) | Osmolythaltige zubereitung zur anwendung bei trockenen schleimhäuten | |
WO2008148572A1 (de) | Antiinflammatorische wirkstoffkombinationen zur behandlung von erkrankungen der haut und schleimhäute | |
WO2008148573A2 (de) | Arzeimittel mit einer wirkstoffkombination enthaltend pantothensäure oder deren derivate zur behandlung von allergischen symptomen | |
EP2714005A1 (de) | Nasale pharmazeutische formulierung enthaltend fluticason | |
EP2200603B1 (de) | Osmolyte zur behandlung von allergisch bedingten atemwegserkrankungen | |
EP1526870B1 (de) | Kombination von loteprednoletabonat und dfho zur behandlung von atemwegserkrankungen, allergischen erkrankungen, asthma und copd | |
EP2320878B1 (de) | Monoterpene für die behandlung von atemwegserkrankungen, insbesondere bronchopulmonalen erkrankungen | |
DE60315426T2 (de) | Pharmazeutische zusammensetzung enthaltend einen pde4 oder pde3/4 inhibitor und eine histaminrezeptorantagonisten | |
DE10064950A1 (de) | Thixotropes Nasenspray | |
DE69812028T2 (de) | Creatine Derivate für Asthma | |
US5993782A (en) | Therapeutic method for reversing hyposmia in a human patient | |
DE202006005924U1 (de) | Zusammensetzung zur Behandlung von Rhinitis | |
AT501376B1 (de) | Glucokortikoid-hältiges arzneimittel | |
Trigg et al. | Local antihistamines. | |
AT413078B (de) | Verwendung eines puffers auf basis von apfelsäure für die herstellung einer nasal applizierbaren zubereitung | |
EP2174690A1 (de) | Kombinationspräparat mit Cinnarizin und Dimenhydrinat zur Behandlung von Schwindel | |
DE60202299T2 (de) | Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten | |
Foglé-Hansson et al. | DSCG eye drops in allergic rhino-conjunctivitis | |
DE3943208A1 (de) | Pharmazeutisches praeparat zur behandlung von heiserkeit | |
EP3458156A1 (de) | Materialien und verfahren zur behandlung von chronischem husten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12745769 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2836025 Country of ref document: CA |
|
REEP | Request for entry into the european phase |
Ref document number: 2012745769 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012745769 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2014511774 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2013/013879 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201391686 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2012265231 Country of ref document: AU Date of ref document: 20120524 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 13337 Country of ref document: GE Kind code of ref document: P |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013030260 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14122561 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 112013030260 Country of ref document: BR Kind code of ref document: A2 Effective date: 20131126 |